Fundamentals of antibody-related therapy and diagnostics

Drugs of Today

Volumn 45, Issue 3, 2009, Pages 199-211

  Albrecht, Huguette ^a   Rodosevich, James A ^b,c   Babich, Michael ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c ImmvaRx Inc   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ANTIBODY; ARCITUMOMAB TC 99M; BASILIXIMAB; BEVACIZUMAB; CAMPATH H; CAPROMAB PENDETIDE IN 111; CERTOLIZUMAB PEGOL; CETUXIMAB; CNJ 016; DACLIZUMAB; ECULIZUMAB; EDRECOLOMAB; EFALIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB IN 111; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; NOFETUMOMAB TC 99M; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TGN 1412; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA ANTIBODY; VERLUMA;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC ASTHMA; ANGINA PECTORIS; ANKYLOSING SPONDYLITIS; ANTIBODY STRUCTURE; AUTOIMMUNE DISEASE; BREAST CANCER; CARDIAC GRAFT REJECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DRUG MANUFACTURE; HEAD AND NECK CANCER; HEART INFARCTION; HEMOLYSIS; HUMAN; HYBRIDOMA; IMMUNOASSAY; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; LUNG CANCER; MULTIPLE SCLEROSIS; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIATIC ARTHRITIS; RECOMBINANT DNA TECHNOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SQUAMOUS CELL CARCINOMA; ULCERATIVE COLITIS; VACCINIA; VIRUS INFECTION;

EID: 67749143885     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.3.1341343     Document Type: Review

References (48)

1. Babich, M. Antibody-based therapies and diagnostics. iDrugs [15th World Congr Pharmacol (July 2-7, Beijing] 2006] 2006, 9(9): 600-603
2. Reichert, J.M., Valge-Archer, V.E. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007, 6(5) 349-356 (Pubitemid 46696550)
3. Molecular Immunology: A Textbook. Atassi, M.Z., van Oss, C.J., Absolom, D.R. (Eds.). Marcel Dekker, New York 1984.
4. Clark, M.R. IgG effector mechanisms. Chem Immunol 1997, (65): 88-110.
5. Holliger, P., Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23(9): 1126-36. (Pubitemid 41486394)
6. Hoogenboom, H.R. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005, 23(9): 1105-1116
7. Mazor, Y., Van, B.T., Mabry, R., Iverson, B.L., Georgiou, G. Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol 2007, 25(5): 563-565 (Pubitemid 46834839)
8. Albrecht, H., DeNardo, S.J. Update: Recombinant antibodies: From the laboratory to the clinic. Cancer Biother Radiopharm 2006, 21(4): 285-304. (Pubitemid 44689683)
9. Padlan, E.A. Anatomy of the antibody molecule. Mol Immunol 1994, 31(3): 169-217.
10. Weiner, L.M. Fully human therapeutic monoclonal antibodies. J Immunother 2006, 29(1): 1-9.
11. Chu, L., Robinson, D.K. Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 2001, 12(2): 180-187 (Pubitemid 32247406)
12. Carson, K.L. Flexibility - the guiding principle for antibody manufacturing. Nat Biotechnol 2005, 23(9): 1054-1058
13. Darnell, H., Streatfield, S.J., Wycoff, K. Medical molecular farming: Production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci 2001, 6(5): 219-26. (Pubitemid 33145916)
14. Lazar, G.A., Dang, W., Karki, S. et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006, 103(11): 4005-4010
15. Pither, R. PET and the role of in vivo molecular imaging in personalized medicine. Expert Rev Mol Diagn 2003, 3(6): 703-713 (Pubitemid 37428958)
16. Woodward, W.A., Sulman, E.P. Cancer stem cells: Markers or biomarkers? Cancer Metastasis Rev 2008, 27: 459-470
17. Goldenberg, D.M., DeLand, F., Kim, E. et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978, 298(25): 1384-1386 (Pubitemid 8358628)
18. Moffat, F.L., Pinsky, C M , Hammershaimb, L., Petrelli, N.J., Patt, Y.Z., Whaley, F.S., Goldenberg, D.M. Clinical utility of external immunoscintigraphy with the IMMU-4 technitium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. J Clin Oncol 1996, 14(8): 2295-2305 (Pubitemid 26264881)
19. Kamb, A., Wee, S., Lengauer, C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov 2007, 6(2): 115-120
20. Wu, A.M., Senter, P.D. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005, 23(9): 1137-1146
21. Bagshawe, K.D., Springer, C.J., Searle, F., Antoniw, P., Sharma, S.K., Melton, R.G., Sherwood, R.F. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988, 58(6): 700-703 (Pubitemid 19033380)
22. Nie, S., Xing, Y., Kim, G.J., Simons, J.W. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007, 9: 257-88
23. Adams, G.P., Weiner, L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23(9): 1147-1157
24. Jain, M., Venkatraman, G., Batra, S.K. Optimization of radioimmunotherapy of solid tumors: Biological impediments and their modulation. Clin Cancer Res 2007, 13(5): 1374-1382 (Pubitemid 46450425)
25. Goldenberg, D.M., Sharkey, R.M. Novel radiolabeled antibody conjugates. Oncogene 2007, 26(25): 3734-3744
26. Johnson, P., Glennie, M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003, 30(1, Suppl. 2): 3-8. (Pubitemid 36337346)
27. DeNardo, G.L. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med 2005, 35(3): 202-211
28. Sievers, E.L. Efficacy and safety of gemtuzumab ozogamicm in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 2001, 1(5): 893-901. (Pubitemid 33769747)
29. Keating, M.J., Flinn, I., Jain, V. et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002, 99(10): 3554-3561 (Pubitemid 34534522)
30. Kim, E.S., Khuri, F.R., Herbst, R.S. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001, 13(6): 506-513 (Pubitemid 33027904)
31. Goldstein, N.I., Prewett, M., Zuklys, K., Rockwell, P., Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1(4): 1311-1318
32. Mendelsohn, J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20(18, Suppl.) 1S-13S. (Pubitemid 35051707)
33. Yang, X.D., Jia, X.C., Corvalan, J.R., Wang, P., Davis, C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001, 38(1): 17-23. (Pubitemid 32194591)
34. Ferrara, N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 2002, 29(6, Suppl. 16): 10-14
35. Presta, L.G., Chen, H., O'Connor, S.J. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57(20): 4593-4599 (Pubitemid 27441066)
36. Carter, P., Fendly, B.M., Lewis, G.D., Sliwkowski, M.X. Development of Herceptin. Breast Dis 2000, 11: 103-111
37. Sundaresan, S., Penuel, E., Sliwkowski, M.X. The biology of human epidermal growth factor receptor 2. Curr Oncol Rep 1999, 1(1): 16-22.
38. Nahta, R., Esteva, F.J. HER-2-targeted therapy: Lessons learned and future directions. Clin Cancer Res 2003, 9(14): 5078-5084 (Pubitemid 37413555)
39. McCarron, P.A., Olwill, S.A., Marou, W.M.Y, Buick, R.J., Walker, B., Scott, C.J. Antibody conjugates and therapeutic strategies. Molecular Interventions 2005, 5(6): 368-380
40. Damle, N.K. Antibody-drug conjugates ace the tolerability test. Nature Biotechnol 2008, 26(8): 884-885
41. Wrammert, J., Smith, K., Miller, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453: 667-671 (Pubitemid 351769295)
42. Zwick, M.B., Gach, J.S., Burton, D.R. A welcome burst of human antibodies. Nature Biotechnol 2008, 26 (8): 886-887
43. Adams, G.P., Schier, R., McCall, A.M. et al. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res 2001, 61(12): 4750-5. (Pubitemid 32691886)
44. Chapman, A.P., Antoniw, P., Spitali, M., West, S., Stephens, S., King, D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999, 17(8): 780-783 (Pubitemid 29365106)
45. Qiu, X.Q., Wang, H., Cai, B., Wang, L.L., Yue, S.T. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol 2007, 25(8): 921-929 (Pubitemid 47236913)
46. Haurum, J.S. Recombinant polyclonal antibodies: The next generation of antibody therapeutics? Drug Discov Today 2006, 11(13-14): 655-660
47. Stebbings, R., Findlay, L., Edwards, C. et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007, 179(5): 3325-31.
48. Brady, L.J. Antibody-mediated immunomodulation: A strategy to improve host responses against microbial antigens. Infect Immun 2005, 73(2): 671-678